Sharon X Xie

List of Publications by Year in Descending Order

53 papers	5,109 citations	31 h-index	53 g-index
53 ext. papers	6,146 ext. citations	8.5 avg, IF	4.93 L-index

#	Paper	IF	Citations
53	Signature laminar distributions of pathology in frontotemporal lobar degeneration.. *Acta Neuropathologica*, **2022**, 143, 363	14.3	0
52	Tau deposition patterns are associated with functional connectivity in primary tauopathies.. *Nature Communications*, **2022**, 13, 1362	17.4	0
51	The development and convergence of co-pathologies in Alzheimer's disease. *Brain*, **2021**, 144, 953-962	11.2	14
50	Distinct characteristics of limbic-predominant age-related TDP-43 encephalopathy in Lewy body disease. *Acta Neuropathologica*, **2021**, 143, 15	14.3	2
49	Distribution patterns of tau pathology in progressive supranuclear palsy. *Acta Neuropathologica*, **2020**, 140, 99-119	14.3	84
48	Subjective Cognitive Complaint in Parkinson's Disease Patients With Normal Cognition: Canary in the Coal Mine?. *Movement Disorders*, **2020**, 35, 1618-1625	7	12
47	Primary Tau Pathology, Not Copathology, Correlates With Clinical Symptoms in PSP and CBD. *Journal of Neuropathology and Experimental Neurology*, **2020**, 79, 296-304	3.1	12
46	Trends in oral anticoagulant co-prescription with antiepileptic drugs among adults with epilepsy, 2010-2018. *Epilepsy and Behavior*, **2020**, 113, 107550	3.2	2
45	Limbic-predominant age-related TDP-43 encephalopathy differs from frontotemporal lobar degeneration. *Brain*, **2020**, 143, 2844-2857	11.2	22
44	TMEM106B Effect on cognition in Parkinson disease and frontotemporal dementia. *Annals of Neurology*, **2019**, 85, 801-811	9.4	23
43	Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders. *Annals of Neurology*, **2019**, 85, 259-271	9.4	41
42	CSF tau and β-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders. *Neurology*, **2018**, 90, e1038-e1046	6.5	43
41	Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. *Brain*, **2018**, 141, 2181-2193	11.2	245
40	APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease. *Movement Disorders*, **2018**, 33, 289-297	7	24
39	Evaluating the Patterns of Aging-Related Tau Astrogliopathy Unravels Novel Insights Into Brain Aging and Neurodegenerative Diseases. *Journal of Neuropathology and Experimental Neurology*, **2017**, 76, 270-288	3.1	71
38	Neuropsychological Subgroups in Non-Demented Parkinson's Disease: A Latent Class Analysis. *Journal of Parkinson's Disease*, **2017**, 7, 385-395	5.3	15
37	Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. *Lancet Neurology, The*, **2017**, 16, 55-65	24.1	273

36	Regional brain amyloid-β accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia. *PLoS ONE*, **2017**, 12, e0177924	3.7	25
35	Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration. *Annals of Neurology*, **2017**, 82, 247-258	9.4	28
34	Research consent capacity varies with executive function and memory in Parkinson's disease. *Movement Disorders*, **2016**, 31, 414-7	7	9
33	Amyloid-Beta Positron Emission Tomography Imaging of Alzheimer's Pathology in Parkinson's Disease Dementia. *Movement Disorders Clinical Practice*, **2016**, 3, 367-375	2.2	22
32	An Alzheimer's Disease-Derived Biomarker Signature Identifies Parkinson's Disease Patients with Dementia. *PLoS ONE*, **2016**, 11, e0147319	3.7	18
31	The Penn Parkinson's Daily Activities Questionnaire-15: Psychometric properties of a brief assessment of cognitive instrumental activities of daily living in Parkinson's disease. *Parkinsonism and Related Disorders*, **2016**, 25, 21-6	3.6	27
30	Development and initial testing of the Penn Parkinson's Daily Activities Questionnaire. *Movement Disorders*, **2016**, 31, 126-34	7	16
29	Longitudinal study of normal cognition in Parkinson disease. *Neurology*, **2015**, 85, 1276-82	6.5	144
28	Correlating Cognitive Decline with White Matter Lesion and Brain Atrophy Magnetic Resonance Imaging Measurements in Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2015**, 48, 987-94	4.3	55
27	Semi-automated quantification of C9orf72 expansion size reveals inverse correlation between hexanucleotide repeat number and disease duration in frontotemporal degeneration. *Acta Neuropathologica*, **2015**, 130, 363-72	14.3	53
26	A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank. *Alzheimer's and Dementia*, **2014**, 10, 477-484.e1	1.2	118
25	Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. *Neurology*, **2014**, 83, 826-33	6.5	59
24	CSF Apo-E levels associate with cognitive decline and MRI changes. *Acta Neuropathologica*, **2014**, 127, 621-32	14.3	51
23	Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases. *Journal of Comparative Neurology*, **2013**, 521, 4339-55	3.4	41
22	Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. *Brain*, **2013**, 136, 2697-706	11.2	434
21	Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale. *Movement Disorders*, **2012**, 27, 242-7	7	202
20	Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis. *Acta Neuropathologica*, **2012**, 123, 395-407	14.3	80
19	Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. *Brain*, **2012**, 135, 3749-56	11.2	179

18	Neuropathologic substrates of Parkinson disease dementia. *Annals of Neurology*, **2012**, 72, 587-98	9.4	316
17	Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. *Brain*, **2012**, 135, 807-18	11.2	171
16	The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. *Journal of Neuroscience*, **2012**, 32, 3601-11	6.6	281
15	Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease. *Brain* , **2012**, 135, 170-80	11.2	122
14	CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. *Acta Neuropathologica*, **2012**, 124, 23-35	14.3	138
13	Building an integrated neurodegenerative disease database at an academic health center. *Alzheimer's and Dementia*, **2011**, 7, e84-93	1.2	45
12	Motor neuron disease clinically limited to the lower motor neuron is a diffuse TDP-43 proteinopathy. *Acta Neuropathologica*, **2011**, 121, 509-17	14.3	44
11	Simulated brain biopsy for diagnosing neurodegeneration using autopsy-confirmed cases. *Acta Neuropathologica*, **2011**, 122, 737-45	14.3	13
10	Neurodegeneration across stages of cognitive decline in Parkinson disease. *Archives of Neurology*, **2011**, 68, 1562-8		149
9	Longitudinal patterns of semantic and episodic memory in frontotemporal lobar degeneration and Alzheimer's disease. *Journal of the International Neuropsychological Society*, **2010**, 16, 278-86	3.1	19
8	Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. *Journal of Neuroscience*, **2010**, 30, 13861-6	6.6	220
7	Pathological 43-kDa transactivation response DNA-binding protein in older adults with and without severe mental illness. *Archives of Neurology*, **2010**, 67, 1238-50		74
6	Rate of decline in Alzheimer disease measured by a Dementia Severity Rating Scale. *Alzheimer Disease and Associated Disorders*, **2009**, 23, 268-74	2.5	29
5	Clinical and pathological continuum of multisystem TDP-43 proteinopathies. *Archives of Neurology*, **2009**, 66, 180-9		192
4	Evidence of multisystem disorder in whole-brain map of pathological TDP-43 in amyotrophic lateral sclerosis. *Archives of Neurology*, **2008**, 65, 636-41		216
3	Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. *Acta Neuropathologica*, **2007**, 114, 221-9	14.3	307
2	Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 227-31	11.5	328
1	Tau spreading is driven by neuronal connectivity in primary tauopathies - evidence from tau-PET and histopathology		1